Discover a new adventure

Entelechy’s business-focused approach ensures they design, develop, and deliver the most effective performance change possible. Whether it’s world-class training, job aids, documentation, coaching, consulting, web-based training, or user help, the solution you get from Entelechy is guaranteed to help you achieve your business goals. They provide a training module with training materials and access to a team of learning and development, and instructional design experts to help execute your program flawlessly.

Vanish Therapeutics

University of Pittsburgh

Pain is the second largest burden on the US health care system, and with the advent of the opioid epidemic it has become apparent that patients with chronic pain do not have sufficient treatment options. A proven non-pharmaceutical method of pain treatment is through nerve and spinal cord stimulators, which are devices that are implanted in the body and use electrical signals to control and modulate the perception of pain. In addition, patients report that their pain is controlled long after electrical stimulation has stopped, and the nerve stimulator market has grown to over $3Billion per year. However, these stimulators often require surgery to implant, can cost more than $30,000 and have excessively high failure rates which are estimated to be over 30%, requiring revision operations and rapidly increasing costs to over $100,000 for a single device.

AbSeek Bio

Vanderbilt University

The human immune system participates in complex interactions with virtually all other systems in the body. In particular, the B-cell component of the adaptive immune response plays a role in various disease settings, including infectious disease, cancer, autoimmunity, cardiovascular, hematologic, neurologic diseases, and others. In addition, antibodies (a product of B cells) are effectively used in diagnostics, therapy, and prevention. To address these significant challenges with current technologies for B cell characterization and antibody discovery, we recently developed a novel technology that, for a given sample, enables the mapping of antibody sequence to antigen specificity from a single high-throughput experiment for a large number of antigens and B cells at a time.

Qunnect

https://www.f6s.com/company/qunnect#about Quantum-secure networking leverages the physical-encryption of photons to enable unprecedented sensitivity and speed of detecting eavesdroppers/hackers. Several barriers exist to broad implementation of scalable quantum networking in the real-world. Foremost, devices supporting quantum transactions, analogous to digital telecom, need to be invented. These devices must be deployable in the real-world and, ideally, also compatible with existing infrastructure, like optical fiber beds.

Tharzen

Relying on developers to do web app maintenance is expensive and time-consuming. Many content management system (CMS) operators like Wordpress claim you can 'do it yourself' visually, but after 20-50 plugins, visual interfaces fall short as many dependencies fail. Tharzen offers a visual editing interface for any live website under any CMS, even hard-coded and dynamic web apps.

synLubricin

Cornell University

Lubrication is critical in biology for tasks such as joint flexing and eye movement, but aging and disease can reduce natural lubrication. Current lubrication solutions either exhibit a short half-life (such as cortisone and hyaluronic acid) or poor long-term bio-compatibility (such as exogenous lubricants like glycerin-mineral oil), leaving a market opportunity to develop a durable, bio-compatible lubricant. synLubricin is a stable, and scalable, long-term bio-lubricant for joints, eyes, and medical devices. synLubricin has been developed in FDA-approved human cell culture systems and is able both to resist cellular adhesion and lubricate biological surfaces, such as cartilage. synLubricin is searching for a co-founder to help develop this venture opportunity.

Qrypt

https://www.crunchbase.com/organization/qrypt

Sarxion Biologics

The shortage of human tissues for surgical applications has driven the market to identify alternatives, including polymeric and biologic materials. Animal tissue, particularly pig, is closing the gap in the critical shortage of human tissue. Current polymeric and conventional biologics exhibit a high degree of complications, in part due to the lack of adequate integration with the surrounding tissues. Sarcio has developed a superior porcine biologic material that addresses the integration deficiencies of polymeric and conventional biologics. Our material is prepared from pigs carrying a single gene knockout resulting in highly integration-competent decellularized tissues. Sarcio’s decellularized tissues are prepared using routine manufacturing methods and are demonstrably superior to conventional polymeric and biological scaffolds. Sarcio’s first planned application will be for hernia repair, a procedure that is performed up to 1 million times annually in the United States.

Eleven P15

University of Colorado

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults. IPF is a fatal disease with median survival at 3-5 years. While there exist several clinical approaches to treating IPF, few therapeutics have been clinically proven to provide significant benefits to patients. Eleven P15 is uniquely positioned for early detection and early intervention of IPF. The pivotal discovery of a common polymorphism in the promoter of MUC5B (rs35705950) has been associated with IPF and pulmonary fibrosis associated with rheumatoid arthritis, and this polymorphism increases the production of mucus.

ColdQuanta

Case Western Reserve University

When atoms are cooled to a few millionths of a degree above absolute zero, they take on quantum properties. Lasers are used to arrange the atoms, hold them in place, run computations on them, and read out the results. Quantum calculations, communications, and sensing are the result. This quantum technology can be used to solve some of the world’s most challenging problems.

SmartScan2

SmartScan2 is revolutionizing secure identification applications with unclonable polymer film-based, scalable technology. Most, if not all security devices in use today can be corrupted, counterfeited, or easily interpreted. Examples of these devices include personal identification cards, passports, pharmaceutical product tracking, currency, and product identification tags. One good example of this corruption involves credit cards. The fifty year old “magnetic strip” technology on a credit card has been corrupted by the use of illegal credit card “skimmers” attached to the credit card readers, and reported in the local news as prevalent on gas pumps and ATMs. The newer “chip” technology on credit cards can also be corrupted by the use of credit card skimmers which are becoming more prevalent in similar locations. SmartScan2's ID security is “unclonable” since it is vastly more difficult to corrupt, counterfeit or interpret the relevant information.

Pearl Bio

Investor: khosla ventures. Pearl Bio is an early-stage venture pioneering design and production of next-generation therapeutics and biomaterials for medical applications and beyond. Biology is constrained to the 20 natural amino acids, limiting the ability to site-specifically modify therapeutic proteins to improve half-life, tissue targeting, or assembly. In contrast, chemical synthesis of therapeutics enables access to greater functional diversity, but template-directed synthesis is challenging. Pearl Bio unites the precision of biology with the unlimited diversity of chemistry in a transformative platform that produces therapeutics and biomaterials with tunable properties for applications in oncology, immunology, and rare disease.

Rarebase Therapeutics

(Highcape Capital presented a profile Jan 2022) Rarebase Therapeutics is focused on overcoming cancer chemo-resistance. The scientific merits of Rarebase are based on a series of groundbreaking discoveries made by Andrew Xiao’s lab at Yale School Medicine. They have revealed that the increased presence of a novel, critical base in DNA (N6-methyl adenine) is the major culprit for cancers to acquire resistance. The main goal of Rarebase Therapeutics is to identify chemical inhibitors to block the synthesis of this base, thereby overcoming resistance of cancers to standard therapies.

Innerworld

Vanderbilt University

A virtual therapy world that is designed to respond to the patient and increase their engagement. What it says here in the approach description is exactly the same as what it says in the description. Innerworld has created a virtual therapy world that is designed to respond to the patient and increase their engagement. The platform allows users to explore and work through their challenges, emotions, and behaviors while learning cognitive behavioral therapy based life changing tools.

Intron Therapeutics

Pathogenic fungi are a major public health threat, causing failure of implanted organs and devices, neonatal mortality and much more. Unfortunately, it is difficult to develop specific drugs against these infections because fungal cells are a lot like those in people: we are both eukaryotes that share a similar set of enzymes and pathways. To address this problem, the Pyle lab has specifically targeted the unique RNA metabolism of fungal cells, giving rise to a new generation of nontoxic drugs that are ready for development and implementation. This has received a Blavatnik Award in May 2019.

BioBina

Columbia University

Effective treatment of abdominal and thoracic cancers requires a more targeted and improved penetration of therapeutics in order to reduce off-target side effects and increase efficacy. BioBina has developed a treatment strategy which utilizes existing radiation therapy with an increased specificity and penetration of the therapeutic to the affected tissue. The technology has been developed for ovarian cancer and has the potential to be extended to a multitude of abdominal and thoracic cancers.

Surgical ai

Harvard University

Operating rooms are often not efficient and are costly to hospitals. Solutions to increasing efficiency neglect to monitor errors in real time which can be stopped and improve efficiency from the time of the incident. This technology pairs artificial intelligence with real time monitoring of operating room procedures to increase efficiency of hospital operating rooms.

Six-month mortality risk estimation from electronic medical record

University of Minnesota

Utilizes a lightweight algorithm and machine learning collected for 8 variables during the first 48 hours of hospitalization to predict the risk of 6-month mortality. Researchers at the University of Minnesota have developed a lightweight algorithm using machine learning for predicting the risk of 6-month mortality at the time of hospital admission. Using just 8 different variables collected during the first 48 hours of hospitalization, this algorithm predicted death within 6-months with an AUC of 0.92. The discriminative ability of this algorithm has been shown to be significantly better than historical estimates of clinician performance. This algorithm can be a critical tool in supporting clinical decision-making at admission and in evaluating suitable options such as transfer to tertiary referral center, serious illness care-conversations in high-risk patients, patient/family counseling, and palliative care utilization.

Prediction Health

University of California, Davis

Makes documentation, compliance, and operational excellence easier by reading and analyzing free form notes and EHR data for Physical Therapist’s compliance and documentation purposes. An artificial intelligence company that is improving patient care. Prediction Health is streamlining clinician workflows and administrator busywork to improve patient care and efficiency. They make documentation, compliance, and operational excellence easy by reading and analyzing free form notes and EHR data for PT's compliance and documentation purposes.

Gateway Bio

Duke University

Gateway Bio is developing an innovative “PEG-like” drug conjugation technology that eliminates the antigenicity issues surrounding PEGylation today. Gateway Bio was specifically formed to translate several scientific breakthroughs from the lab of Professor Chilkoti at Duke University into commercially viable products and processes by combining the expertise of the academic scientists closest to these technologies with the business acumen of experienced start-up professionals. The initial core technology of Gateway Bio is based on several key patents on POEGMA conjugates that have been successfully licensed from Duke by Gateway Bio. Our novel method of creating PEG-like conjugates could be applied to generics, existing drugs, newly developed drugs or any of the PEGylated pharmaceuticals currently on the market. There are currently 15 FDA-approved peglyated drugs, with dozens more in clinical trials. Sales of the two most successful pegylated products, Pegasys and Neulasta, exceeded $5 billion in 2011.

Invictus BCI

Cornell University

Using machine learning and neuroscience, Invictus BCI has created an affordable prosthetic control interface that has a greater movement capability and is more comfortable. Developer of a brain-controlled interface technology intended to create prosthetic control interfaces that can restore near natural functionality. The company's technology leverages new advances in machine learning and neuroscience to create a prosthetic control interface that has more intuitive control, greater movement capability, enabling patients to get access to greater comfort all while being far less expensive. TE

Protein Architects

Monoclonal antibodies (mAbs) are a $300B market, about $20B in diagnostics and $30B in antiviral therapeutics. Yet antibodies require poorly scaling, expensive mammalian cells, vary with batch, are environmentally unstable, and are subject to escape by viral strain evolution. Protein Architects is developing beta solenoid proteins as “molecular Legos” for applications in self-assembly of nanoparticle based devices and materials. Our polyvalent, environmentally robust viral decoy proteins for antigen diagnostics and therapeutics can be scalably produced in microbial GMP facilities at 1/50 the cost per binder yet bind up to 1000000x stronger than antibodies. As receptor decoys, they align with viral evolution, and modular human design makes immunocompatible therapeutics. We are seeking seed financing and regulatory advising on our in development viral decoy antibody substitutes for SARS-CoV-2 antigen diagnostics and therapeutics. We are positioned to make a difference in this pandemic, and future viral threats.

QuantHub

University of California, San Diego

Founded in 2018, QuantHub provides an efficient yet rigorous vetting platform for hiring data professionals and a modern, in the flow of work, learning platform focused on both AI skills for analytics teams and data literacy skills for the entire enterprise. QuantHub is a SaaS subscription-based platform written for data scientists by data scientists, providing skill tests, data challenges, and skill development plans completely tailored to the unique characteristics of the advanced analytics space.

Palm Therapeutics

Palm Therapeutics is a San Diego based biotechnology startup, and member of JLABS@San Diego, in the early stages of development of an innovative class of drugs known as depalmitoylating molecules (DPALMs). The DPALM strategy was developed in the Devaraj Lab at The University of California San Diego by Dr. Andrew Rudd and Prof. Neal Devaraj. Our technology targets post-translational protein palmitoylation and represents a fundamentally new approach to inhibiting protein function. In preliminary studies, NRas-targeted DPALMs have shown in vitro and in vivo efficacy in NRas-driven melanoma models, and in September 2020, we were awarded a Phase I SBIR from NIH/NCI to pursue this indication.

UV-C N95 Sterilization

Currently there are several solutions under consideration for disinfecting N95 respirators for re-use, with UV-C as the preferred solution because of ease of deployment and widespread applicability. Problematically, present UV-C disinfection solutions are limited by shadowing, which prevents exposure of the masks to the required effective dose of UV irradiation. The inventors utilized UV-C light field modeling and extensive test measurements to develop a proprietary arrangement of lamps for disinfecting. The configuration eliminates shadowing, allowing for full irradiation and disinfecting of the contaminated N95 respirator surface in the shortest amount of time.

SkyNano Technologies

Vanderbilt University

Using patent-pending technology developed at Vanderbilt University, our technique overcomes cost and scaleability limitations associated with traditional manufacturing techniques, while also giving commercial viability to carbon conversion technologies through the introduction of a high-value secondary material produced from greenhouse gas inputs. Our technique relies on electrochemistry, rather than solely catalysis, and results in a highly efficient process to convert atmospheric carbon dioxide into useful functional nanomaterials.(6.2022 - SkyNano was selected to receive $2M in funding from the U.S. Department of Energy Advanced Research Projects Agency-Energy (ARPA-E). The funding is part of the ARPA-E HESTIA program, which prioritizes overcoming barriers associated with carbon-storing buildings, including scarce, expensive and geographically limited building materials. As of August 2022, SkyNano has raised ~$8.5M (million) in non-dilutive funding from a variety of federal, state, and commercial sources.)

Yoma Biosciences

DNA damage can be detrimental to cells as it can lead to mutagenesis, genotoxicity and tumorigenesis. One of the most frequent forms of DNA damage is 8-oxoguanine (8-OG), which is repaired by OGG1. Bioactive inhibitors of OGG1 and the GO pathway can be useful tools to investigate the connections of this enzyme activity to disease. Yoma Biosciences has developed potent, selective, small-molecule inhibitors of OGG1 and other enzyme targets in the GO pathway. These inhibitors provide useful tools to study the biological roles of OGG1 and also have therapeutic potential for cancer and inflammation. With multiple enzyme targets in the pathway (OGG-1, MTH1, MutYH, …) - currently un-drugged, Yoma has multiple chances for 1st in class candidate discovery.

NextGenET

University of Pittsburgh

Ventilator Associated Pneumonia (VAP) is viewed as an inevitable consequence of long-term ventilator support rather than a preventable infection. In fact, VAP develops in 1 out of 3 intubated patients in intermediate care units. Along with the high prevalence, VAP has an average mortality rate of almost 50%. As a result, hospitals utilize procedural steps to prevent VAP in patients (such as head elevation and maintaining oral hygiene), but these actions fail to adequately prevent the root cause of VAP which is that current endotracheal (ET) tubes, or breathing tubes, do not create a long-term and effective seal in the trachea to prevent bacteria from entering the lungs. These tubes fail to create a proper seal because they employ an inflatable cuff that (1) deflates over time, (2) does not maintain consistent contact with the airway surface, and (3) is susceptible to shifting position with every patient movement. These design flaws allow harmful bacteria to pass the cuff and enter the lungs of patients.

Bacchus Therapeutics

Bacchus Therapeutics is a biotech company that exploits cancer’s hypermetabolic state by targeting specific cancer metabolic pathways. The aberrant expression of MYC is virtually unmatched, making MYC one of the most frequently deregulated oncogenes in human tumors, including, liver, kidney, CNS, hematopoietic, breast, prostate, lung and GI tumors. Human studies and animal models have established that dysregulation of MYC underlies the pathogenesis and aggressiveness of numerous cancers. Our founders, Drs. Gouw and Felsher, discovered that MYC regulates the aberrant lipid metabolism of tumors and that inactivation of key lipid enzymes results in regression of tumors. (Update: After receiving the IGNITE program grant in 2021, Bacchus opened a lab at one of the shared wet benches in the Prince William County Accelerator in early 2022.)

AgileMD

George Washington University

Industry-leading analytic for predicting all hospital-caused deterioration and sepsis. eCART continually monitors patients using real-time data and drives clinical workflows for front-line staff and rapid response teams to prevent failure to rescue. AgileMD eCART is dedicated to improving patient outcomes by leveraging the way data is used. They are part of a revolutionary change in the delivery of healthcare that is being driven by the rapid uptake in technologies related to the capture, storage, and analysis of data. They empower electronic health records to deliver standardized clinical pathways that recommend orders, document decision-making, and save time.

Inleptin Therapeutics

Note: No company is formed yet. Seeking entrepreneur to lead. Opioids remain an indispensable treatment for severe pain despite increased risk for obese patients with tolerance. Of particular concern is opioid-induced respiratory depression (OIRD), especially during sleep, due to comorbid obstructive sleep apnea common in obese patients. Naloxone is the only drug available that can reverse the adverse effects of opioids and prevent death. However, naloxone has limited use because it reverses analgesia and induces withdrawal. A preventive treatment for sleep-related OIRD that does not affect analgesia or induce withdrawal is critical in patients with obesity. GW and JHU researchers found that intranasal leptin can reverse morphine-induced apneas, hypoventilation, and upper-airway obstruction while enhancing analgesic effects in mice with obesity.

EndObetes

Columbia University

While surgical intervention via gastric bypass is effective in patients with obesity and type-II diabetes, the surgery is invasive, expensive and not reversible. Additionally, it is usually not prescribed for patients with BMI <40. Therefore, there is a need for a non-surgical alternative which is safer and less expensive but which mimics the effects of gastric bypass surgery. EndObypass achieves this with an implantable metal stent which runs through the stomach. The device mimics the anatomic and physiological changes caused by surgical procedures, resulting in dramatic weight loss and remission of diabetes. Animal studies with the implanted device have demonstrated proof of concept. The EndObypass technology provides a safe and affordable alternative to gastric bypass surgery.

3rd Arm Inc

University of California, Davis

Articulated Wearables to enhance human productivity. 3rd Arm is prototyping a wearable, articulated robotic device that can be attached to a person at the hip or other location to augment human task productivity. This mechanical "third arm" has many uses such as assisting abled users (e.g. holding additional tools to enhance work), helping disabled users (e.g. providing support and lifting objects), and as a haptic interface for interaction with robotics systems and AR/VR experiences. 3rd Arm is incorporating the latest robotic technology with a newly designed 4-state brake mechanism in joints for advanced operations.

Theranostec

Theranostec have developed a novel, nanoparticle treatment platform allowing for targeted and effective chemotherapy, which can be enhanced with phototherapy, while also lowering toxicity. (UPDATE: Received $3M research funding to develop our approach in companion animals. SBIR awards: NIH - $2M / NIH 2021 - $480K / NIH 2019 - $300K / NIH 2018 - $291K / NIH 2018 $225K )

Aethergen Biosciences

Dartmouth College

Fungal bioproduction makes up 50% of the industrial enzymes market, a $10B market with a CAGR of 7.1% yearly. Fungal production of enzymes requires that large, dense cultures of cells be aerated properly. Dense cultures, however, become very viscous; stirring these cultures to provide oxygen can damage cells. Aethergen introduces mutations into fungi which convey morphology beneficial for fermentation processes, and lower oxygen consumption by half. This alleviates the need for a tradeoff between culture density and oxygen transfer. Aethergen can thus offer both enzyme manufacturers and strain improvement companies a more efficient process, lowering raw material costs and increasing margins.

M^3

University of California, Irvine

We treat faces as if they were feet, and that’s absurd. Unlike feet, faces are 3D, yet we still measure them using 2D objects such as paper cutouts in the massive $6b market to fit people with masks. This doesn’t cut it, and the data backs it up: 50% of Americans don’t wear the CPAP masks they’ve been prescribed because of these fit, comfort, and convenience issues. The only reason we’ve tolerated this is that until recently there has been no better way to get good 3d measurements of your face without lots of specialized tools. We solve this problem by making it as easy as taking a selfie to get precise 3D measurements of your face.

Velox Biosystems

Velox Biosystems plans to develop and launch a rapid diagnostic product for urinary tract infections (UTI), a problem that affects nearly 50 percent of the population at least once in their lifetime. This decision follows the startup’s completion of a recent clinical feasibility test that yielded impactful clinical data for the company to move forward with the next steps in development. Velox Biosystems has created an ultra sensitive rapid detection system that provides for no or minimal sample processing, high throughput scanning of large sample volumes, with single target sensitivity and unprecedented speeds. Utilizing a digital droplet molecular detection platform, we are developing a point of care diagnostic device to address critical unmet needs in the UTI, liquid biopsy, and sepsis spaces. Total available market of over $1 Billion.

BiomeSense

Integrating proprietary technologies, the GutLab, “smart bathroom” technology for continuous patient microbiome tracking & MetaBiome, a cloud-based bioinformatics platform. Novel tools to continuously track, analyze, and store individual microbiome profiles, providing vastly more data than, and at a fraction of the cost of, current practice. Creating the GutLab, a novel “smart bathroom” technology for continuous, at-home microbiome tracking & MetaBiome, a cloud-based bioinformatics platform. This platform is a generational leap over existing measurement tools: (1) much cheaper and more scalable, (2) produces & analyze dense time-series data, unlocking an entire dimension of never-before-accessible biomarkers, and (3) has far higher accuracy & precision, ensuring all data generated can be stored in a single, standardized database – a first for the microbiome field.

MyophonX

Cornell University

Solutions for silent speech production lack innovation, cultural acceptability, and often involve invasive surgery. MyophonX is cutting-edge wearable technology for silent communication, with applications to stroke and laryngectomy patients as well as voice searching.

Carver Biosciences

Princeton University

(Update 9.22 - Closed seed round by Khosla Ventures). Broad-spectrum antiviral therapies do not exist, tragically hindering our ability to respond to viral outbreaks and pandemics. We need new approaches to treat these diseases, as existing therapeutics are very narrow-spectrum and take many years to develop. Carver Biosciences is a startup company developing CRISPR-based therapies for RNA viruses that infect humans. Carver’s approach is a programmable, platform technology that could offer a generalizable solution for treating many viruses, as targeting is dictated by a guide RNA sequence. The underlying technology, CARVER, was developed by founder Cameron Myhrvold during his time as a postdoc at the Broad Institute of MIT and Harvard and was published in Molecular Cell in 2019.

Neurograins

Brown University

The field of brain-machine interfaces has advanced significantly over the past two decades, especially in its successful transition into human clinical trials. However, this progress has relied largely on wired, invasive sensors for the acquisition of neural data with high spatial and temporal resolution. Neurograins represents the first completely wireless network of sensors in neural application, consists of ensembles of implantable, sub-millimeter, individually addressable microchips.

ViewsML

Dartmouth College

Utilizing artificial intelligence in conjunction with the electrocardiogram to help clinicians identify cardiovascular disease more quickly, more accurately, and at a fraction of the cost. Real time capture of microscope video that is digitized, formatted and stored for AI and ML based use to enhance patient diagnosis. ViewsML uses a machine-learning model to predict biomarker expression in patient samples, both spatially and quantitatively. This reduces a 24+ hour process down to a few seconds, saving time and resources that can be redeployed elsewhere in the hospital or laboratory.

STAT3-MS NeuroTherapeutics

Ohio State University

MS patients have an imbalance of Effector and Regulatory cells which causes nerve damage. The solution is a Novel small molecule STAT3 inhibitor, LLL12B, that improves Effector/Regulator cell balance. LLL12b significantly suppresses the disease progression in three murine MS model. There is a great opportunity for this solution as MS is prevalent in 300 people per every 100,000 in the US and is onset in the age range of 20-40.

Pulmera

Carnegie Mellon University

Pulmera enables x-ray visualization of the tracheobronchial tree to aid physicians in guiding endoscopic tools in the pulmonary tract. Early diagnosis and treatment are vital for improving lung cancer survival rates, and tissue biopsy is necessary for diagnosis. However, performing a lung biopsy is difficult due to the complexity of the highly branched airways of the lung, making it difficult to access and obtain the tissue and the procedure can pose a risk to the patient. Electromagnetic navigation bronchoscopy (ENB) is the safest way to obtain a biopsy but diagnostic success is limited by poor real time visualization of significant portions of the lung. Should the biopsy procedure be unsuccessful, patients may then need to have the tissue surgically removed. In a high number of these cases, the nodules are found to be benign. Pulmera will greatly improve the ability to obtain a diagnosis for the patient using ENB.

Rubitection

Rubitection is developing a skin health and wellness system to improve assessment and care management of dermatological, plastic surgery, and vascular conditions with an initial application to early bedsores detection. Bedsores are an $11 billion healthcare problem at affects 2.3 million each year killing 60K. If detected early they can be prevented, but low cost early detection tools are not available. Our Rubitect Assessment System (RAS) empowers any caregiver in hospitals, nursing homes, and in home care to detect bedsore early and support care management. Rubitection’s issued patents, and exclusive worldwide license provide barriers to competitors. The RAS’ low risk FDA pathway allows a quick path to a $4.1 billion US bedsore market. Two recurring revenues supports long term sustainability. Within 5 - 6 years of product launch, Rubitection will generate $48 million in sales using a hybrid sales model. Rubitection will exit through acquisition to a wound care company like Hill-Rom, or 3M.

EnTiCe

Washington University in St. Louis

EnTiCe is developing a low-cost battery for grid reliability. The EnTiCe system is an all-soluble, electrode decoupled and long lasting design that is considerably less expensive than all-Vanadium RFBs ($400/KWh at scale). The EnTiCe battery uses patented membrane and electrode technologies, with the plan to reach <$50/KWh following scale up and commercialization. The initial target market for this redox flow battery is utility scale storage, which is expected to grow at 20% CAGR in the near term with growth concentrated in China, EU and North America.

OptoVibronex

Rutgers University

The current standard for distinguishing between benign and cancerous skin legions require an invasive skin biopsy followed by a waiting period for lab results for diagnosis. OptoVibronix is eliminating the need for invasive skin biopses to diagnose a skin legion as cancerous or benign. The technology scans the skin legion and results in a diagnosis in just 15 minutes. By avoiding skin biospy, it improves the patient experience and efficiency of diagnosis and reduces healthcare costs.

PrevPanc

PrevPanc is developing an improved prophylactic against pancreatitis caused by endoscopic retrograde cholangiopancreatography (ERCP), by targeting two key inflammatory pathways. Post-ERCP pancreatitis can be life-threatening, excruciatingly painful, and costly. PrevPanc is developing a more effective and practical treatment to prevent pancreatitis, with significant improvements beyond current options of indomethacin, stenting, and IV hydration. PrevPanc's therapy is a combination of a calcineurin inhibitor combined with indomethacin to target two distinct inflammatory pathways, achieving higher effectiveness than the current standard of care with minimal change in post-procedure care.

AlvaHealth